These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27716499)

  • 21. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
    Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
    Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
    Winkler ML; Papp-Wallace KM; Bonomo RA
    J Antimicrob Chemother; 2015 Aug; 70(8):2279-86. PubMed ID: 25957381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid detection of ceftazidime/avibactam resistance by MALDI-TOF MS.
    Carvalhaes CG; Ramos AC; Oliveira LCG; Juliano MA; Gales AC
    J Antimicrob Chemother; 2018 Sep; 73(9):2579-2582. PubMed ID: 29878121
    [No Abstract]   [Full Text] [Related]  

  • 26. Structural and Kinetic Characterization of Diazabicyclooctanes as Dual Inhibitors of Both Serine-β-Lactamases and Penicillin-Binding Proteins.
    King AM; King DT; French S; Brouillette E; Asli A; Alexander JA; Vuckovic M; Maiti SN; Parr TR; Brown ED; Malouin F; Strynadka NC; Wright GD
    ACS Chem Biol; 2016 Apr; 11(4):864-8. PubMed ID: 26731698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.
    Li J; Lovern M; Riccobene T; Carrothers TJ; Newell P; Das S; Talley AK; Tawadrous M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations.
    McLeod SM; Patey SA; Huband MD; Nichols WW
    Int J Antimicrob Agents; 2017 Apr; 49(4):437-442. PubMed ID: 28242258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftazidime with β-lactamase inhibitor approved for complicated infections.
    Thompson CA
    Am J Health Syst Pharm; 2015 Apr; 72(7):511. PubMed ID: 25788500
    [No Abstract]   [Full Text] [Related]  

  • 30. Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia.
    Algwizani A; Alzunitan M; Alharbi A; Alsaedy A; Aljohani S; Alalwan B; Gramish J; Alothman A
    J Infect Public Health; 2018; 11(6):793-795. PubMed ID: 29706317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
    Shields RK; Potoski BA; Haidar G; Hao B; Doi Y; Chen L; Press EG; Kreiswirth BN; Clancy CJ; Nguyen MH
    Clin Infect Dis; 2016 Dec; 63(12):1615-1618. PubMed ID: 27624958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa.
    Xipell M; Bodro M; Marco F; Losno RA; Cardozo C; Soriano A
    Int J Antimicrob Agents; 2017 Feb; 49(2):266-268. PubMed ID: 27979500
    [No Abstract]   [Full Text] [Related]  

  • 33. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups.
    Li J; Lovern M; Green ML; Chiu J; Zhou D; Comisar C; Xiong Y; Hing J; MacPherson M; Wright JG; Riccobene T; Carrothers TJ; Das S
    Clin Transl Sci; 2019 Mar; 12(2):151-163. PubMed ID: 30221827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
    Giani T; Cannatelli A; Di Pilato V; Testa R; Nichols WW; Rossolini GM
    Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.
    Jones RN; Holliday NM; Krause KM
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5036-9. PubMed ID: 26014937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy Review of Ceftazidime-Avibactam.
    Yaeger A; Kappes J
    S D Med; 2017 May; 70(5):229-231. PubMed ID: 28813756
    [No Abstract]   [Full Text] [Related]  

  • 37. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    Int J Antimicrob Agents; 2017 Feb; 49(2):239-242. PubMed ID: 27939093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of a Klebsiella pneumoniae KPC cellulitis and gut decolonization with ceftazidime/avibactam in a migrant from Libya.
    Carannante N; Pallotto C; Bernardo M; Di Caprio G; Tascini C
    J Chemother; 2018 May; 30(3):183-184. PubMed ID: 29336224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition.
    Choi H; Paton RS; Park H; Schofield CJ
    Org Biomol Chem; 2016 Apr; 14(17):4116-28. PubMed ID: 27072755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.